<DOC>
	<DOCNO>NCT02405364</DOCNO>
	<brief_summary>The purpose determine whether induction consolidation treatment Carfilzomib , Lenalidomide Dexamethasone ( CRd ) , within intensive program , warrant investigation clinical trial .</brief_summary>
	<brief_title>Front-line Therapy With Carfilzomib , Lenalidomide , Dexamethasone Induction</brief_title>
	<detailed_description>The primary objective evaluate sCR rate combination carfilzomib , lenalidomide dexamethasone newly diagnose multiple myeloma patient completion consolidation therapy . It 's multicenter , open label , non randomize , phase II study . 46 patient enrol . Induction : 4 cycle 28 Days Carfilzomib/Lenalidomide dexamethasone Stem Cell Harvest : High dose Cyclophosphamide intensification consolidation : 4 cycle 28 Days Carfilzomib/Lenalidomide dexamethasone Maintenance : Lenalidomide 13 cycle 28 day</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients diagnose multiple myeloma base new International Myeloma Working Group Subjects must symptomatic myeloma least one CRAB criterion Subjects must treat previously systemic therapy multiple myeloma Pregnant lactating female Evidence mucosal internal bleeding and/or platelet refractory Acute active infection require treatment Treatment localize radiotherapy interval end radiotherapy initiation protocol therapy low 2 week Treatment corticosteroid exceed equivalent 160 mg dexamethasone 2week period initiation therapy Subjects eligible high dose therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Carfilzomib</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Patient 65 year</keyword>
	<keyword>initial management</keyword>
</DOC>